BeyondSpring Inc. (BYSI) Stock

BeyondSpring Inc. (BYSI) is a Healthcare stock trading at $0.72 (as of 2026-08-21), with a market capitalization of $29.61M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing cancer therapies, with its lead asset Plinabulin, a selective immune-modulating microtubule-binding agent. It also develops Plinabulin in combination with immuno-oncology agents (including PD-1/PD-L1 and CTLA-4 antibodies) and radiation, and has additional small-molecule immune agents in preclinical stages and a drug development platform.

Understand BeyondSpring Inc.: how it makes money

BeyondSpring develops cancer therapies, centered on Plinabulin, a selective immune-modulating microtubule-binding agent, and its development programs aim to reach commercialization if regulators approve the Phase III and combination results; its latest reported period shows no revenue, so its economics depend on future approval and commercialization.

Profit potential is tied to Plinabulin's path from late-stage clinical results to regulatory approval and future commercialization, with additional value drivers from planned or ongoing combination development with immuno-oncology agents.

Business quality (Weak): Single-asset, late-stage clinical narrative is clear from the provided facts, but there is no segment breakdown and no operating KPI provided, and the latest period shows no revenue.

Bull case

  • Lead asset has completed Phase III trials: Plinabulin has completed Phase III clinical trials for prevention of chemotherapy-induced neutropenia and for treatment of later-stage non-small cell lung cancer.
  • Combination strategy with immuno-oncology agents: The company is developing Plinabulin in combination with immuno-oncology agents including nivolumab (PD-1 antibody) and ipilimumab (CTLA-4 antibody) for NSCLC.

Bear case

  • No revenue reported in the latest period: In the latest reported period (2024-06-30), revenue is listed as 0.0B, indicating limited or no commercialization captured in reported results.
  • Very large operating loss profile: The latest reported operating margin is -742.2%, reflecting substantial operating losses, typical of a clinical-stage development company.
Valuation — source: SEC EDGAR (first-party)
Price$0.72
Market Cap$29.61M
FCF Yield-94.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Financial Health — source: SEC EDGAR
Altman Z-Score-22.49 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderDecheng Capital LLC ($6.23M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOLan Huang
Employees40
CountryUS
IPO Date2017-03-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • MIRA Pharmaceuticals, Inc. (MIRA)
  • Actuate Therapeutics Inc (ACTU)
  • IGC Pharma, Inc. (IGC)
  • Lantern Pharma Inc. (LTRN)
  • Daré Bioscience, Inc. (DARE)
  • NextCure, Inc. (NXTC)
  • NanoViricides, Inc. (NNVC)
  • Optimi Health Corp. (OPTH)
BYSI earnings history · BYSI institutional & insider holders · BYSI KPIs & operating metrics · BYSI financials · BYSI investor presentations & press releases · BYSI SEC filings · BYSI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.